Fed. Circ. Wipes Out Medicines Co.'s Angiomax Patents

Law360, New York (July 2, 2015, 3:46 PM EDT) -- The Federal Circuit on Thursday invalidated two of The Medicines Co.'s patents for the blood thinning drug Angiomax, finding that the claimed process was offered for sale before the patent applications were filed, in a victory for Hospira Inc., which is planning a generic version of the drug.

The decision reversed a lower court ruling that found that the patents are valid, but that Hospira didn't infringe them. The Medicines Co. appealed the noninfringement finding, while Hospira appealed the finding that the patents are valid....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.